Hosted on MSN8mon
Boehringer and Lilly report data from heart failure treatment trialData revealed a 10% relative decline in risk on the primary composite endpoint for participants treated with Jardiance compared to placebo, which did not reach statistical significance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback